Human Papillomavirus Prevalence and Vaccination Rates Among Users of Pre-Exposure Prophylaxis for Human Immunodeficiency Virus Prevention.
| Autor: | Rotert P; University of Kansas Medical Center, Kansas City, KS, USA., Wheldon C; Temple University, Philadelphia, PA, USA., Kownack J; University of Kansas Medical Center, Kansas City, KS, USA., Sullivan-Blum Z; University of Kansas Medical Center, Kansas City, KS, USA., Cokingtin B; Cleveland Clinic Foundation, Cleveland, OH, USA., Khetani K; Rutgers New Jersey School of Medicine, Newark, NJ, USA., Ndeti K; University of Kansas Medical Center, Kansas City, KS, USA., Skyes K; University of Kansas Medical Center, Kansas City, KS, USA., Ramaswamy M; University of Kansas Medical Center, Kansas City, KS, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of primary care & community health [J Prim Care Community Health] 2022 Jan-Dec; Vol. 13, pp. 21501319221110411. |
| DOI: | 10.1177/21501319221110411 |
| Abstrakt: | Introduction: Our study provides data on the prevalence of human papillomavirus (HPV) related disease and vaccination rates among users of pre-exposure prophylaxis (PrEP) in a primary care clinic. Results highlight an opportunity to partner HIV and HPV prevention efforts. Methods: This is a retrospective chart review of PrEP patients in an urban Midwestern Family Medicine clinic. We conducted univariate analyses for HPV vaccination status and the prevalence of any HPV-related disease. We then examined bivariate relationships between vaccination status and insurance coverage, provider type, and age. Results: Of all 78 PrEP patients identified, 21.8% (n = 17) were vaccinated. Of the 59 patients 45 years or younger, 28.8% (n = 17) were vaccinated. There was no association between insurance or provider type and vaccination status. Patients 26 years or younger were 3 times more likely to be vaccinated than those ages 27 to 45 (56.3% vs 18.6%, P = .0011). Three unvaccinated patients had HPV-related disease. Conclusions: Despite ongoing risk of HPV infection and frequent interaction with the medical system, this study found most PrEP users continue to be unvaccinated. This is a significant missed opportunity for HPV prevention. With the FDA approval of the HPV vaccine for individuals age 9 to 45, PrEP patients in this age range would benefit from clinicians partnering HPV vaccination with PrEP prescribing. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|